Adipocyte differentiation inhibiting peptide and adipocyte diffe

Details Adipocyte differentiation inhibiting peptide and adipocyte diffe Adipocyte differentiation inhibiting peptide and adipocyte diffe

1995-09-25

1998-05-26

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530331, 426656, 435 711, A61K 3800

Patent

active

057564671

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

This invention relates to a novel adipocyte differentiation inhibiting peptide, adipocyte differentiation inhibiting agent using the peptide as an active component thereof, a specific health food (so-called physiologically physiolosically functional food) possessing the function of inhibiting adipocyte differentiation, and an animal feed possessing the function of inhibiting adipocyte differentiation. It further relates to a specific health food (so-called physiolosically functional food) incorporating therein a proteolysate containing the adipocyte differentiation inhibiting peptide mentioned above, possessing the function of inhibiting adipocyte differentiation and an animal feed possessing the function of inhibiting adipocyte differentiation. This invention allows prevention and therapy of obesity of men or animals and cardiovascular diseases attendant on obesity such as hypertension and arteriosclerosis. It further permits improvement of the meat quality of domestic animals and cultured fish.


BACKGROUND ART

It is held that excessive ingestion of fat and carbohydrate induces obesity and hyperlipidemia and even develops hypertension and arteriosclerosis ultimately. The desirability of repressing the absorption of fat and carbohydrate and diminishing the accumulation of fat has, therefore, been finding enthusiastic recognition.
Infants, on exposure to excessive ingestion of nutrition, suffer increase of adipocytes and assume the state which may well be called potential obesity. By this reason, it has been reported that the repression of the increase of the number of adipocytes particularly in infants results directly in the prevention of the obesity and the cardiovascular diseases which may well be called complications of obesity in children and consequently in adults.
For the therapy of obesity and hyperlipidemia, such measures as limitation of meal, ingestion of diet food (such as, for example, fibers), and even administration of various medicines have been in vogue. The medicines now in popular use include dextran sulfate which enhances the lipoprotein lipase activity in blood, nicomol which inhibits absorption of lipid, especially cholesterol, and clofibrate and pravastatin which are agents for improving metabolism of lipid, for example.
Unfortunately, the limitation of meal is an agony for persons obliged to pursue this exercise and the administration of such medicines as mentioned above possibly entrains side effects.
The domestic animals and the cultured fish are now given enriched feed which is aimed at promoting growth. As a result, the domestic animals and the cultured fish have unduly high fat contents in their meat. The enriched feed, accordingly, compels the domestic animals and the cultured fish to suffer excessive intake of fat and degradation of the taste of their meats below the level meeting consumers' fancy.
Recently, an oligopeptide-containing substance developed by researchers including one of the inventors of the instant patent application has been already applied for patent (International Patent Disclosure W089/06970). A technique similar thereto is disclosed in JP-A-02-154,693.
In these patent publications, it is clearly remarked that certain species of oligopeptides are effective in improving metabolism of lipids.
The oligopeptide-containing substance disclosed in the patent application mentioned above is a mixture of hydrolysates of protein in composition. The amino acid sequence of the true active component of this substance, namely a peptide as an active component, is not demonstrated.
This fact implies that the peptide-containing substance has a too low purity to be utilized as a medicine. This substance permits no perfect quality control because the substance, when incorporated in food, cannot be easily quantified separately from the peptide inherent in the food.
Under the circumstances, the identification of the true active component, i.e. the peptide as an active component, of the peptide-containing substance under discussion is posed as a task.
This inv

REFERENCES:
Agricol. Biol. Chem., vol. 52, No. 1, pp. 95-98, Norio Ishibashi, et al., "Taste of Proline-Containing Peptides", 1988.
Boehlen et al., "Purification of peptides: an efficient procedure for the separation of peptides from amino acids and salt.", Int. J. Pept. Protein Res. (1980), 16(4), 306-10.

Affiliated with

Also associated with

Rating

Adipocyte differentiation inhibiting peptide and adipocyte diffe does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adipocyte differentiation inhibiting peptide and adipocyte diffe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adipocyte differentiation inhibiting peptide and adipocyte diffe will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1960118